Replies to post #8825 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: GTC’s unnamed mAb FoB’s

>The four or five mabs coming off patent I take it are Rituxan (targeted by the CD20 project), Avastin and other cancer mabs?<

Avastin is probably not one of them because it has a considerable amount of US patent time remaining.

Other than Rituxan, the likely mAb FoB’s that GTC is thinking about include Herceptin, Remicade, and Enbrel, IMO. Erbitux could be one too.

All of these meet the “large volume” rationale for transgenic production. (Enbrel is strictly speaking not a mAb, but it is usually thought of as one.) Regards, Dew